AnHeart Therapeutics
Biotech/Healthcare - New York, NY, US
AnHeart Therapeutics Employees
AnHeart Therapeutics Senior Management
AnHeart Therapeutics Details
AnHeart Therapeutics is a clinical-stage global biopharmaceutical group company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a best-in-class next-generation ROS1 inhibitor currently in Phase 2 trials for the first-line TKI-naïve and second-line TKI-pre-treated patients with ROS1 fusion positive non-small cell lung cancer (NSCLC). The Company's pipeline also includes AB-218, a mIDH1 inhibitor in Phase 2 trials with good brain penetration for multiple solid tumors with mIDH1 mutations and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor or chemotherapies in NSCLC or other solid tumors.
AnHeart Therapeutics Technologies
Email Providers
Outlook
Load Balancers
Nginx
CMS
WordPress.org
Fonts
Typekit
Other
Mobile Friendly